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Abstract 
Background: Radical radiotherapy, with or without concomitant chemotherapy forms the mainstay of 
organ preservation approaches in mucosal primary head and neck cancer. Despite technical advances in 
cancer imaging and radiotherapy administration, a significant proportion of patients fail to achieve a 
complete response to treatment. For those patients who do achieve a complete response, acute and late 
toxicities remain a cause of morbidity. A critical need therefore exists for imaging biomarkers which are 
capable of informing patient selection for both treatment intensification and de-escalation strategies. 
Methods/design: A prospective imaging study has been initiated, aiming to recruit patients undergoing 
radical radiotherapy (RT) or chemoradiotherapy (CRT) for mucosal primary head and neck cancer 
(MPHNC). Eligible patients are imaged using FDG-PET/CT before treatment, at the end of week 3 of 
treatment and 12 weeks after treatment completion according to local imaging policy. Functional MRI 
using diffusion weighted (DWI), blood oxygen level-dependent (BOLD ) and dynamic contrast enhanced 
(DCE) sequences is carried out prior to, during and following treatment. Information regarding treatment 
outcomes will be collected, as well as physician-scored and patient-reported toxicity. Discussion: The 
primary objective is to determine the correlation of functional MRI sequences with tumour response as 
determined by FDG-PET/CT and clinical findings at 12 weeks post-treatment and with local control at 12 
months post-treatment. Secondary objectives include prospective correlation of functional MRI and PET 
imaging with disease-free survival and overall survival, defining the optimal time points for functional MRI 
assessment of treatment response, and determining the sensitivity and specificity of functional MRI 
sequences for assessment of potential residual disease following treatment. If the study is able to 
successfully characterise tumours based on their functional MRI scan characteristics, this would pave the 
way for further studies refining treatment approaches based on prognostic and predictive imaging data. 
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Abstract
Background: Radical radiotherapy, with or without concomitant chemotherapy forms the mainstay of organ
preservation approaches in mucosal primary head and neck cancer. Despite technical advances in cancer imaging and
radiotherapy administration, a significant proportion of patients fail to achieve a complete response to treatment. For
those patients who do achieve a complete response, acute and late toxicities remain a cause of morbidity. A critical
need therefore exists for imaging biomarkers which are capable of informing patient selection for both treatment
intensification and de-escalation strategies.
Methods/design: A prospective imaging study has been initiated, aiming to recruit patients undergoing radical
radiotherapy (RT) or chemoradiotherapy (CRT) for mucosal primary head and neck cancer (MPHNC). Eligible patients
are imaged using FDG-PET/CT before treatment, at the end of week 3 of treatment and 12 weeks after treatment
completion according to local imaging policy. Functional MRI using diffusion weighted (DWI), blood oxygen level-
dependent (BOLD) and dynamic contrast enhanced (DCE) sequences is carried out prior to, during and following
treatment. Information regarding treatment outcomes will be collected, as well as physician-scored and patient-
reported toxicity.
Discussion: The primary objective is to determine the correlation of functional MRI sequences with tumour response
as determined by FDG-PET/CT and clinical findings at 12 weeks post-treatment and with local control at 12 months
post-treatment. Secondary objectives include prospective correlation of functional MRI and PET imaging with disease-
free survival and overall survival, defining the optimal time points for functional MRI assessment of treatment response,
and determining the sensitivity and specificity of functional MRI sequences for assessment of potential residual disease
following treatment. If the study is able to successfully characterise tumours based on their functional MRI scan
characteristics, this would pave the way for further studies refining treatment approaches based on prognostic and
predictive imaging data.
Trial registration: Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRN12616000534482 (26 April 2016).
Keywords: Head and neck cancer, MRI, Functional imaging, Hypoxia, Predictive role, Chemoradiation, Dynamic
contrast-enhanced MRI, Diffusion-weighted imaging
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Background
Mucosal primary head and neck cancer (MPHNC) has
an estimated incidence of over 900,000 cases per year,
and is associated with significant mortality, causing more
than 350,000 deaths per year[1]. Organ preservation
strategies involve the administration of a radical dose of
radiation therapy, usually with concomitant chemother-
apy, producing 5-year overall survival rates of between
30 and 50% [2]. Despite technical improvements in
radiotherapy, significant toxicity may result from these
treatments [3, 4].
Prognostication and treatment strategies are in-
formed by clinical features [5] and increasingly by
tumour biological features, notably preceding infec-
tion with oncogenic strains of human papilloma virus
(HPV) [6, 7]. Reliable imaging biomarkers may there-
fore provide useful data to facilitate adaptive ap-
proaches including treatment intensification for poor
responders and de-intensification for good responders
[8]. Such strategies may improve the therapeutic ratio
by reducing dose to organs at risk and increasing
dose to areas harbouring subvolumes of more resist-
ant tumour.
Positron-emission tomography using 18F–fluorodeoxy-
glucose (FDG-PET) is currently a standard investigation
for initial staging of MPHNC. Retrospective studies have
described FDG-PET’s performance in assessing disease
following radical radiotherapy [9, 10] and its value in
decision-making around surgical salvage has been demon-
strated in a prospective trial [11]. Some limitations remain
however, with the possibility of false-positive results due
to benign tissue inflammation and of false-negative results
due to limited spatial resolution.
Magnetic resonance imaging (MRI) has an established
role in diagnosis and staging of MPHNC, and its use in
radiotherapy planning continues to expand [12]. MRI has
superior spatial resolution, better soft tissue definition and
does not employ ionising radiation. Furthermore, func-
tional sequences can provide additional information on
tissue composition and biology which is not revealed by
standard anatomical T1 and T2 weighted scans.
Diffusion-weighted imaging (DWI) characterises tis-
sue based on movement of water within a volume.
The diffusivity of water molecules depends on micro-
structural features of the tissue, such as cellular size
and density, and may be quantified with the apparent
diffusion coefficient (ADC). Its applications in the
upper aerodigestive tract were previously limited by
technical factors such as susceptibility artefact from
air-tissue interfaces and low signal-to-noise ratio.
Modern scanning techniques have been able to over-
come many of these issues, and DWI measurements
before, during and following RT have been investi-
gated as a diagnostic and prognostic tool [13–18].
Dynamic contrast-enhanced (DCE) MRI provides in-
formation on abnormal tumour vasculature, by assessing
the travel of gadolinium contrast agent between intra-
vascular and extracellular extravascular space (EES) by
means of sequential T1-weighted scans with high tem-
poral resolution. With knowledge of the pre-contrast T1
tissue values, and the concentration-time course of con-
trast in feeding blood vessels, pharmacokinetic model-
ling can generate quantitative parameters for analysis of
tumour perfusion [19]. These include Ktrans (the volume
transfer constant between blood plasma and EES), Kep
(the rate constant between EES and blood plasma) and
Ve (the fractional volume of EES). The values of these
parameters, as well as their distribution in the volume
imaged, have been investigated as potential imaging bio-
markers both before and after treatment for MPHNC
[20–30].
Blood oxygen level–dependent (BOLD) MRI utilises
local changes in magnetic susceptibility due to the pres-
ence of paramagnetic deoxyhaemoglobin. An increase in
deoxyhaemoglobin shortens transverse relaxation time
T2*, giving a qualitative indication of tissue hypoxia [31].
The rate of transverse relaxation R2* (1/T2*) can be
measured with a multiple-echo gradient echo sequence
and has been shown to correlate with tissue hypoxia as
measured by polarographic electrodes and immunohis-
tochemistry [32–34]. Pre-clinical and early clinical re-
sults suggest that R2* may be a useful biomarker for
radiation response and for treatment outcomes [35–37].
Our group completed a pilot study of functional MRI
and FDG-PET in a cohort of patients undergoing radical
radiotherapy for MPHNC, indicating that carrying out
sequential DWI and R2* studies before, during and after
radiotherapy was feasible. Initial results, including corre-
lations between imaging studies have been published,
while mature data regarding clinical outcomes are
awaited [18]. Following this we have initiated a prospect-
ive observational study named “MRI in MPHNC”, which
aims to gather data on the utility of functional imaging se-
quences with DWI, DCE and BOLD MRI as biomarkers
for prediction and assessment of treatment response.
Methods
Study design and consent
This study is a prospective single arm observational trial
of patients undergoing curative intent primary radiother-
apy, with or without chemotherapy, for MPHNC at Liver-
pool and Campbelltown Hospitals. Patients are identified
and evaluated by the multidisciplinary team. Informed
consent is obtained by medically trained personnel as per
the trial delegation log. Administrative support, including
travel funding for study scans, is provided by clinical trials
unit staff.
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Hypotheses
1. Functional MRI can be used as a reliable imaging
biomarker in prediction of treatment response
(radiotherapy ± chemotherapy) in MPHNC
2. Functional MRI can be used as an alternative
functional imaging study to FDG-PET scan in asses-
sing response after radiotherapy ± chemotherapy
3. Functional MRI can differentiate between recurrent
or residual malignant disease and post-treatment tis-
sue changes following radiotherapy ± chemotherapy
Objectives
Primary objective
To determine the correlation of pre-, during treatment
and post-radiotherapy (± chemotherapy) functional MRI
with tumour response at 3 months by FDG-PET scan
and with local control at 12 months.
Secondary objectives
1. To prospectively correlate different MRI sequences
and FDG-PET findings with disease-free survival
(DFS) and overall survival (OS)
2. To determine the best time to perform MRI during
radiotherapy treatment for assessing tumour
response and local control
3. To determine the sensitivity and specificity of
functional MRI sequences compared with FDG-PET
in assessment of potential residual and recurrent
MPHNC following definitive radiotherapy
4. To assess consistency of image registration, signal
information and associated analyses over a relevant
time frame in a representative subset of patients
Endpoints
Primary endpoints
Correlation of functional MRI sequences with PET-CT
at 3 months following treatment and local control at
12 months, including:
 Measurement of restricted water diffusion as on
DWI, which can be a marker of high cellularity
within a tumour, using ADC values, ΔADC and
parameter maps of ADC.
 Measurement of tumour perfusion characteristics
from DCE-MRI, using parameter maps and calcu-
lated values based on inflow and outflow (Ktrans, Kep)
as well as degree of contrast enhancement of tissues
(Relative Signal Intensity, RSI).
 Tumour size as defined on anatomical imaging using
T2-weighted and/or T1-weighted Volume Interpo-
lated Breathhold Examination (VIBE) Dixon MRI.
Secondary endpoints
Correlation of different MRI measurements with 1 and
2 year DFS and OS including:
 Determination of the ability of DWI for detecting
residual or recurrent cancer
 Assessment of functional MRI in correlation with
FDG-PET metabolic response at 3 months and local
control at 12 months
Subject selection
Inclusion criteria
 18 years or older
 Have the ability to give informed consent
 Histologically-proven invasive mucosal primary
squamous cell carcinoma of head and neck region or
patients with tumours strongly suspicious for
mucosal primary head and neck cancer due to
clinical features AND fine needle aspiration (FNA)
cytology assessment
 Primary mucosal head and neck cancer (≥T2 and/or
≥N1) AND no evidence of metastatic disease on
staging PET/CT or CT (chest ± abdomen ± pelvis)
 Patient undergoing curative intent primary
radiotherapy ± chemotherapy
Exclusion criteria
 Contraindication to MRI studies
 Significant claustrophobia
 Pacemaker/implantable defibrillator
 Implanted metals e.g. Intraocular clips
 Known allergic reaction to gadolinium (Gd)-
DTPA
 Previous radiotherapy to the area to be treated
 Primary cancer surgery to the affected area
 Other malignancy within 5 years of the current
diagnosis, with the exception of successfully treated
basal cell or squamous cell skin carcinoma, in situ
melanoma, or carcinoma in situ of the cervix
Early withdrawal of subjects
If a patient expresses wishes to withdraw from the trial,
site staff will explain the importance of maintaining
follow-up. A patient may withdraw, or be withdrawn,
from the trial for the following reasons:
 Unacceptable toxicity
 Requests or requires early discontinuation for any
reason
 Intercurrent illness which prevents further
treatment/follow-up
 Withdrawal of consent for treatment by patient
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 Develops, during the course of the study, symptoms
or conditions listed in the exclusion criteria
 Investigator discretion
The investigator will also withdraw all subjects from
the study if the study is terminated. Subjects are free to
withdraw from the study at any time upon their request
or the request of their legally acceptable representative.
Patients may re-consent if they change their mind fol-
lowing withdrawal, to resume participation on this trial.
The patient will however remain in the trial for the pur-
poses of follow-up and data analysis unless they specific-
ally request otherwise.
Radiotherapy
All participants will receive standard treatment accord-
ing to locally agreed protocols [38], based on inter-
national evidence-based practice guidelines. This study
does not involve a treatment intervention or additional
ionising radiation exposure. Therefore, there will not be
any additional radiation dose or related side effects by
participating in this trial. All imaging performed with
ionising radiation is part of standard clinical practice.
Chemotherapy
All participants will be treated according to locally agreed
protocols [38], based on international evidence-based
practice guidelines. Therefore, there will not be any add-
itional chemotherapy related side effects by participating
in this trial.
Imaging
Imaging schedule
Functional MRI studies are carried out prior to com-
mencing treatment, then weeks 2, 3, 5 and 6 during
treatment, followed by 1 month and 3 months post-
treatment (Fig. 1).
Imaging procedures
All patients scanned on a 3 T wide bore scanner (Skyra,
Siemens, Erlangen, Germany) using a 20-channel head
and neck coil (Fig. 2). Morphological and functional se-
quences are obtained in the same scan session.
Morphological MRI
Sagittal T2 TIRM (turbo inversion recovery magnitude).
Axial T2 TSE DIXON water-only.
Coronal T2 TSE DIXON water-only.
Axial T1 DIXON water-only, pre- and post-contrast.
Functional MRI
Coronal BOLD
 Gradient echo imaging with multiple echoes
 5 mm slice thickness, 2 averages, 8 slices through
region of interest
 In-plane resolution 1.7 × 1.7 mm
 TR 500 ms, TE 2.46 to 56.58 ms (12 echoes, 4.92 ms
spacing)
Axial DWI
 Readout segmentation of long variable echo-trains
(RESOLVE) sequence
 3 mm slice thickness
 In-plane resolution 0.4 × 0.4 mm
 3-scan trace, monopolar
 b = 50 s/mm2 with one average, b = 800 s/mm2
with 3 averages, calculated image at b = 1400 s/mm2
 Bandwidth 868 Hz/Px
Repeat coronal BOLD
 Gradient echo imaging with multiple echoes
 5 mm slice thickness, 2 averages, 8 slices through
region of interest
 In-plane resolution 1.7 × 1.7 mm
 TR 500 ms, TE 2.46 to 56.58 ms (12 echoes, 4.92 ms
spacing)
DCE scans
 2 x 3D coronal T1 VIBE (volumetric interpolated
breath-hold examination) scans for T1-mapping
 2° and 15° flip angles
 3 mm slice thickness
 In-plane resolution 1 × 1 mm
 Acquisition time 1 m 21 s
 Bandwidth 440 Hz/Px
 TWIST (Time-resolved angiography With
Interleaved Stochastic Trajectories)
 Slice thickness 3 mm
 In-plane resolution 1 × 1 mm
 TR 3.06 ms, TE 1.35 ms
 Bandwidth 800 Hz/Px
 i.v. gadobutrol (Gadovist, Bayer) 0.1 mL/kg,
capped at a maximum of 7.5 mL; injection of
contrast immediately before 4th measurement,
4 ml/s with 20 ml saline flush
 Scan for total 60 timepoints, temporal resolution
5.64 s
 Data acquired for 5 m 33 s
Hop on hop off sub-study scans (week −3 to 0 only)
 Patients who consent to the sub-study get up from
the couch and are repositioned a few minutes later
 Axial T1, T2 and DWI scans are repeated
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Statistical plan
Sample size determination
Based on our previous study using week 3 FDG-PET scan
in head and neck cancer patients, the following sample
size calculation is made. To test a significant FDG-PET
complete metabolic response (CMR) rate of 87% in the
MRI-positive group versus an FDG-PET CMR rate of 51%
in the MRI-negative group, the study will need to recruit
55 patients in total to reach 80% power (at 5% significance
level). This number is based on an assumption that the
MRI-positive group and MRI-negative group will be bal-
anced (e.g. 50%:50% but is powered to allow up to a
40%:60% biased ratio). It is anticipated that recruitment
will be completed in 24 months. Patients will be offered
participation in the “hop on hop off” sub-study, with a re-
cruitment goal of 20.
Assessment of MRI sequences
MRI scans will be determined as a good response
(e.g. positive) or poor response (e.g. negative) based on
the following definitions for endpoint analysis:
DWI
High ADC values will be considered a good response
(positive MRI) and low ADC values a poor response
(negative MRI).
DCE MRI
A reduction in blood inflow and outflow (e.g. Ktrans and
Kep) will be considered a good response (positive MRI)
and either no change or an increase will be considered a
poor response (negative MRI).
BOLD
A reduction in R2* values will be considered a good response
(positive MRI) and either no change or increase in R2* values
will be considered a poor response (negative MRI).
Definition of local control
FDG-PET response at 12 weeks will be defined as a
complete metabolic response, partial metabolic response,
stable metabolic disease or progressive metabolic disease
based on visual assessment by the nuclear medicine
Fig. 1 Treatment, imaging and clinical assessment schedule for MRI in MPHNC study
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physician’s report. Local control for patients will be assessed
at 12 months as indicated by having no evidence of local
disease on clinical (including endoscopic) examinations and
imaging studies at 12 months. Tumour response will be
assessed using Response Evaluation Criteria In Solid Tu-
mors (RECIST) criteria version 1.1[39] which is the inter-
nationally recognised gold standard assessment method on
the evaluation of therapeutic response in solid tumours.
Statistical analysis
Statistical analyses will be performed by using software
SPSS and p < 0.05 will be considered statistically significant.
Chi-square test will be used to compare the prevalence of
FDG-PET CMR between MRI-positive and negative
groups. Comparisons of the ADC values/maps of pre-,
intra- and post-treatment DWI images will be performed
by using one way analysis of variance (ANOVA) test. Com-
parisons of the DCE parameters such as Ktrans, Kep, area
under the curve (AUC) at initial 60 and 90 s of pre-, intra-
and post-treatment will be performed by using the Kruskal-
Wallis test. To determine the sensitivity and specificity of
DWI and DCE parameters for FDG-PET CMR and
12 month local control, Kappa association statistics will be
used. Receiver operator characteristics (ROC) will be used
to obtain an optimal threshold for individual MRI
parameters.
Data collection
General baseline demographic data will be collected.
Other data collection can be defined by the 6 general
categories below:
Quality of life
 Baseline
 Final week of chemoradiotherapy
 Follow up visits 1, 3, 6, 12, 18, 24, 30 and 36 months
post treatment
 Assessed using University of Washington Quality of
Life Questionnaire (UW-QOL v4)[40]
Blood tests
 Baseline
 Weeks 2, 3, 5, 6
 Follow up visits 1 and 3 months post-treatment
 Consist of full blood count and basic biochemistry
panel including urea, creatinine, sodium, potassium
and chloride
Toxicity
 Acute toxicities – dry mouth, dysphagia, pain,
weight loss, oral mucositis, radiation dermatitis,
dygeusia,
 Baseline, weekly during treatment
 Follow up visits 1 and 3 months post treatments
 Late toxicities – dry mouth, skin induration,
osteonecrosis of jaw, voice alteration, oral mucositis,
dysphagia, hearing, tracheostomy, laryngectomy,
tube feeding
 At follow up visits 3, 6, 12, 18, 24, 30 and
36 months post treatment
 Using CTCAE version 4.0
Fig. 2 Research scan patient setup for MRI in MPHNC study
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 Serious adverse events to be reported to the HREC
for review
Swallowing assessment
 Baseline
 Final week of chemoradiotherapy
 Follow up visits 1, 3, 6, 12, 18, 24, 30 and 36 months
post treatment
Scans
 Functional MRI scans as per Fig. 1 and Imaging
procedures above
 As per standard of care, a PET/CT will be carried
out at week 3 of chemoradiotherapy treatment and
then at 3 months following completion of
chemoradiotherapy treatment
Treatment data
 The dose and duration of treatment will be
recorded.
Data handling and record keeping
All imaging datasets will be de-identified and stored in a
secure research drive at the Cancer Therapy Centre, Liver-
pool Hospital after recruiting patients to the study. Con-
tours will be performed by radiation oncologists/fellows
and saved on the research drive. Datasets will be imported
into MATLAB (MathWorks Inc. Massachusetts, United
States) and similar mathematical analysis programs for
data-analysis. Data analysis will be in line with study aims.
The investigator site file and patient study file will be
kept at the Ingham Institute Liverpool and will be ac-
cessible only by clinical trials staff.
Confidentiality
Subject confidentiality is strictly held in trust by the par-
ticipating investigators, research staff, the sponsoring in-
stitution and their agents. The study documentation,
data and all other information generated will be held in
strict confidence. No information concerning the study
or the data will be released to any unauthorized third
party, without prior written approval of the HREC and
the principal investigator. Clinical information will not
be released without written permission of the subject,
except as necessary for monitoring by Human Research
Ethics Committee (HREC) or regulatory agencies.
Records retention
It is the investigators’ responsibility to retain study es-
sential documents for at least 15 years after the comple-
tion of this clinical trial. All information will be stored in
the Radiation Oncology research office located at the
Ingham Institute, Liverpool Hospital, either on a pass-
word protected computer or in files kept in a locked
room. Access to this information will be limited to the
principal investigator, research assistants and statistician
as authorized by the delegation log.
Timelines/milestones
The study started recruitment after ethics approval was
granted. A sample size of 55 has been selected for this
study for the reasons discussed above. Initial projections
suggested this could be achieved within 24 months,
however this timeframe will be reviewed as recruitment
progresses.
Publication and dissemination
The results of the study will be submitted for publication
in peer-reviewed journals and for presentation at scien-
tific meetings. Participants in the study will be notified
of study results in writing.
Discussion
In recent years intensity-modulated RT, along with ad-
vanced diagnostic and on-treatment imaging technolo-
gies, have improved the therapeutic ratio in head and
neck cancer [41]. The enhanced ability to dose-paint and
the recognition of heterogeneity within tumours gives
rise to the promise of functional image-guided RT
(fIGRT), where subvolumes may be treated to differing
doses according to imaging-derived parameters. Longitu-
dinal diffusion-weighted imaging has already been
shown to be feasible in MRI-guided cobalt radiotherapy
systems [42], suggesting that the addition of functional
as well as anatomical imaging may serve to improve out-
comes with these systems, as well as in the MRI-guided
linear accelerators in development.
Our protocol builds on our earlier work which estab-
lished the feasibility of serial functional MRI during a
course of treatment for MPHNC. Refinements to the im-
aging protocol include the addition of DCE sequences,
which may be expected to add further value [43], and
the expansion of the BOLD sequence to acquire multiple
slices across a volume, an imaging technique which may
be more reliable than BOLD imaging carried out on sin-
gle slices [44]. The additional information gained from
the enhanced suite of imaging sequences in the current
study will help to define which sequences, at which time
points, can be used to adapt and personalise radiother-
apy treatment. This information will then feed into the
design of interventional studies of adaptive RT.
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